Leukemia, Myeloid, Acute clinical trials

The registry lists 3,667 studies for Leukemia, Myeloid, Acute across more than 10 countries. 816 are recruiting or about to start. 2,595 of them are mainly about Leukemia, Myeloid, Acute (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 7 narrower conditions too, such as Leukemia, Monocytic, Acute: 3,785 studies, 831 open.

ClinicalTrials.gov finds 4,303 studies for Leukemia, Myeloid, Acute. How that becomes 3,663 here

This page counts the studies the registry files under Leukemia, Myeloid, Acute, and those it files under no condition that list Leukemia, Myeloid, Acutethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

4,303Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−115Filed under a narrower condition, counted on its own pageLeukemia, Promyelocytic, Acute 68 · Leukemia, Mast-Cell 23 · Leukemia, Monocytic, Acute 14 · Leukemia, Megakaryoblastic, Acute 4 · Leukemia, Eosinophilic, Acute 4 · Leukemia, Erythroblastic, Acute 1
−123List Leukemia, Myeloid, Acute as a condition, but the registry did not file them under itMost often written as “Secondary Acute Myeloid Leukemia” (20), “Recurrent Childhood Acute Myeloid Leukemia” (19), and “Acute Myeloid Leukemia in Remission” (19). The registry filed them under other conditions only, most often Precursor Cell Lymphoblastic Leukemia-Lymphoma (44) and Myelodysplastic Syndromes (39).
−402Match it another way198 name it in the title, 73 in a keyword, and 131 by a synonym or other text the search reads.
3,663The count on this page75 of them list Leukemia, Myeloid, Acute in their own words; the registry filed them under no condition.

Get an email when these change. Save the Leukemia, Myeloid, Acute studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 1,596
Recruiting: 625
Terminated: 538
Status unknown: 307
Active, not recruiting: 223
Not yet recruiting: 165

Phase

Phase 2: 1,594
Phase 1: 1,499
Phase 3: 337
Early Phase 1: 55
Phase 4: 41

Where

United States: 2,137
China: 473
France: 341
Germany: 282
Italy: 229
Canada: 205

Who runs them

M.D. Anderson Cancer Center (197) · National Cancer Institute (NCI) (154) · Fred Hutchinson Cancer Center (111) · City of Hope Medical Center (63) · The First Affiliated Hospital of Soochow University (57) · Masonic Cancer Center, University of Minnesota (56) · Memorial Sloan Kettering Cancer Center (49) · Institute of Hematology & Blood Diseases Hospital, China (46)

What is being tested here

Drugs under test in Leukemia, Myeloid, Acute studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Venetoclax	112	25	197
Azacitidine	70	30	210
Cytarabine	37	28	241
Fludarabine	34	13	191
Cyclophosphamide	23	9	155
Decitabine	19	13	117
Busulfan	16	14	116
Revumenib	15	2	17
Melphalan	14	8	67
CPX-351	14	6	50

Drug classes tested here Antimetabolites 150 open · Alkylating agents 44 open · Tyrosine kinase inhibitors (TKIs) 43 open · Calcineurin inhibitors 11 open · HDAC inhibitors 11 open

Coming up

95phase 3 studies under way

306studies finish main data collection within a year22 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia · Phase 3 · Peking University People's Hospital
Dec 2026DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML · Phase 3 · The Second Affiliated Hospital of Kunming Medical University
Dec 2026Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study · Phase 3 · Nanfang Hospital, Southern Medical University
Dec 2026Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML · Phase 3 · The First Affiliated Hospital of Soochow University
Dec 2026Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia · Phase 3 · Yehui Tan
Dec 2026MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) · Phase 3 · Zhongnan Hospital
Feb 2027Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) · Phase 3 · PedAL BCU, LLC
Apr 2027IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML · Phase 3 · National Research Center for Hematology, Russia
Apr 2027VEN+IDAC vs IDAC in AML · Phase 3 · Guangdong Second Provincial General Hospital
Apr 2027A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 362 (58%) set no upper age limit and 222 (36%) stop at 75 or younger. 145 (23%) take children under 18. 2 (<1%) are for women only and 0 (0%) for men only; 29 (5%) take healthy volunteers.

Recruiting studies that take each age, of 625
Age	Women	Men
10	100 (16%)	100 (16%)
18	579 (93%)	578 (92%)
30	545 (87%)	544 (87%)
40	536 (86%)	535 (86%)
50	537 (86%)	536 (86%)
65	536 (86%)	534 (85%)
75	462 (74%)	460 (74%)
85	387 (62%)	385 (62%)

Across all 3,667 studies, recruiting or not: 35% stop at 75 or younger and 21% at 65; 25% take children; <1% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Leukemia, Myeloid, Acute studies take

Of 490 phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 49 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	49 mo31–76 · 490 studies	40 mo29–62 · 183 studies	52 mo32–87 · 307 studies
Phase 1/2	73 mo48–106 · 226 studies	73 mo45–91 · 92 studies	76 mo49–110 · 134 studies
Phase 2	60 mo38–104 · 443 studies	39 mo33–55 · 57 studies	67 mo40–108 · 386 studies
Phase 2/3	66 mo37–86 · 31 studies	—	—
Phase 3	74 mo39–99 · 120 studies	42 mo30–62 · 42 studies	87 mo66–111 · 78 studies
Interventional, no phase	47 mo25–123 · 139 studies	—	49 mo26–128 · 132 studies
Observational	54 mo36–154 · 160 studies	—	66 mo41–234 · 128 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out